1422435-40-2 Usage
Uses
Dabigatran Etexilate iMpurity D does not have any direct applications in the pharmaceutical or medical industry due to its harmful nature. However, its presence in the medication is crucial to monitor and control for the following reasons:
1. Ensuring Patient Safety:
Dabigatran Etexilate iMpurity D is used as a quality control parameter for ensuring patient safety. The expression is: Dabigatran Etexilate iMpurity D is used as a monitoring parameter for [ensuring patient safety] because of its genotoxic nature.
2. Compliance with Regulatory Guidelines:
Dabigatran Etexilate iMpurity D is used as a compliance indicator for adhering to strict regulations and guidelines set by regulatory authorities. The expression is: Dabigatran Etexilate iMpurity D is used as a compliance indicator for [adhering to strict regulations and guidelines] to limit its presence in the medication.
3. Safe and Effective Medication Use:
Dabigatran Etexilate iMpurity D is used as a control factor for the safe and effective use of Dabigatran Etexilate as a medication for preventing blood clots. The expression is: Dabigatran Etexilate iMpurity D is used as a control factor for [safe and effective medication use] by ensuring its levels are within acceptable limits.
Check Digit Verification of cas no
The CAS Registry Mumber 1422435-40-2 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,4,2,2,4,3 and 5 respectively; the second part has 2 digits, 4 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 1422435-40:
(9*1)+(8*4)+(7*2)+(6*2)+(5*4)+(4*3)+(3*5)+(2*4)+(1*0)=122
122 % 10 = 2
So 1422435-40-2 is a valid CAS Registry Number.
1422435-40-2Relevant academic research and scientific papers
NOVEL REFERENCE MARKERS OF DABIGATRAN ETEXILATE
-
Page/Page column 20, (2013/03/26)
A new method of obtaining chemically pure and pharmaceutically acceptable Dabigatran Etexilate or its pharmaceutical acceptable salt having purity at least about 99% is provided, wherein the content of Dabigatran Etexilate individual impurity is less than 0.03-0.15% as measured by HPLC. A method of removing specific impurities that are generated either due to the intrinsic instability of Dabigatran Etexilate or in process of its preparation is provided too.
